Bryan Johnson, a tech entrepreneur turned biohacker, has become a prominent figure in the quest for immortality. For years, Johnson has invested over $2 million annually in groundbreaking treatments and technologies aimed at slowing down the aging process. From youthful blood transfusions to experimental plasma exchanges, his efforts have captured the public’s attention, positioning him as the face of the modern biohacking movement.
However, Johnson’s latest revelation casts a shadow over his journey. Despite his relentless pursuit of longevity, one of his high-profile anti-aging strategies may have backfired, inadvertently accelerating his aging process. In a recent video posted on his YouTube channel, Johnson opened up about his experience with rapamycin, a drug he believed would extend his lifespan. Unfortunately, it appears to have had the opposite effect.
The Rapamycin Experiment: A Drug That Promised Youth
Rapamycin is an immunosuppressant originally developed for organ transplant patients, but it gained popularity in anti-aging circles after a 2009 study demonstrated its ability to extend the lifespan of mice by up to 14%. Johnson, ever the optimist, decided to experiment with the drug as part of his broader anti-aging regimen.
Encouraged by a promising 2023 study in which 65% of human trial participants reported feeling healthier on rapamycin, he began incorporating it into his daily routine.
For five years, Johnson fine-tuned his dosage of rapamycin, carefully adjusting it to strike a balance between potential benefits and risks. However, instead of rejuvenation, he began experiencing a series of concerning side effects that led him to reevaluate his approach.
Warning Signs: The Unintended Consequences of Rapamycin
As Johnson continued using rapamycin, he began to notice troubling health changes. These included:
- Mouth ulcers
- Slow-healing wounds
- Cholesterol imbalances
- Increased blood sugar levels
But the most alarming symptom was an increase in his resting heart rate, a key indicator of his sleep quality and recovery. This stark contrast to the expected benefits forced Johnson to take a step back and reassess his regimen.
New Research Turns the Tables on Rapamycin
Adding to Johnson’s concerns was a recent study by Yale University, which challenged the long-held belief that rapamycin was an effective anti-aging solution.
The study found that, contrary to prior research, rapamycin may accelerate aging by affecting 16 key epigenetic markers. Instead of slowing down the aging process, it might have been speeding it up — at least for Johnson.
A Moment of Reflection: Transparency Over Embarrassment
Despite the potentially devastating implications of his experience, Johnson has chosen transparency over embarrassment. In his latest video, he humorously acknowledged the situation, laughing along with those who might find his experiment’s failure ironic.
He shared with his followers that he has since discontinued the drug, but emphasized that this misstep was not a reason for him to abandon his quest for longevity.
“I believe it’s important to talk about both the successes and the failures,” Johnson stated. “That’s how we all learn.”
Why did Bryan Johnson stop taking rapamycin?
The short answer: Bryan Johnson stopped taking rapamycin in September 2024 after nearly five years of self-experimentation that began in 2019. He cited persistent side effects: intermittent skin and soft-tissue infections, abnormal lipid readings, elevated glucose, and an increased resting heart rate, plus a 2024 preprint suggesting rapamycin accelerated aging across 16 epigenetic clocks.
That is the part that stings. Johnson was one of rapamycin’s most visible advocates, at one point describing his regimen as among the most aggressive in the longevity world. He tested weekly doses of 5, 6, and 10 milligrams, biweekly 13-milligram doses, and alternating schedules. The side effects did not respond to dosage changes, which is what pushed him to stop entirely. His words on X at the time: with no other underlying causes identified, the team suspected rapamycin, and since dosage adjustments had no effect, they discontinued it.
To keep this honest, the mouse data that started the craze was real and remains real. Harrison et al. published the landmark result in Nature in 2009: rapamycin fed to genetically heterogeneous mice starting at 600 days of age increased maximum lifespan by 14% in females and 9% in males, replicated across three independent laboratories. The problem was never the mice. The problem is that mice are not people, and Johnson’s five-year n-of-1 experiment is the most closely tracked human case we have.
The Community Responds: Mixed Reactions to Johnson’s Honesty
Johnson’s openness has sparked a range of reactions from his audience. Some commenters expressed appreciation for his transparency and scientific approach to failure, praising him for sharing the negative results of his experiment. One user remarked, “It’s shocking how many people don’t understand the value of sharing negative results.”
Others praised his willingness to own up to mistakes, with one commenter saying, “This is one of your best videos by far. Adequate scientific explanation, owning up to the mistake.”
There were also those who, while not fully agreeing with all of Johnson’s methods, expressed admiration for his commitment to exploring the boundaries of human health and longevity. One user quipped, “Tip of the spear. Not sure I agree with all things Bryan Johnson, but I applaud his undertaking this journey and, most importantly, sharing it with the world.”
The High Price of Eternal Youth
Bryan Johnson’s experiment is a high-risk venture that has garnered both admiration and skepticism. While some regard him as a visionary pioneering new frontiers in health and wellness, others view his methods as reckless. Nonetheless, Johnson’s commitment to his anti-aging journey serves as a stark reminder of the unpredictability of biohacking.
In the pursuit of eternal youth, even the most well-researched and calculated experiments can have unintended consequences. Johnson’s story underscores the importance of transparency in biohacking — both the triumphs and the failures contribute to the collective understanding of what it truly means to fight aging.
Conclusion
As the science of longevity continues to evolve, Bryan Johnson’s journey serves as both a cautionary tale and an inspiration. His willingness to share his experiences — including the missteps — highlights the unpredictable nature of biohacking and the complex science behind aging. In a world where anti-aging promises abound, Johnson’s story is a potent reminder that the road to immortality may not always be what it seems.
For more information on longevity and biohacking, check out our comprehensive guide to anti-aging strategies.
2026 refresh: where the rapamycin science actually stands
Three developments matter for anyone who read this story and wondered whether to try rapamycin themselves.
1. The 2024 epigenetic-clocks preprint. A preprint study assessed rapamycin’s effects across 16 epigenetic aging clocks and found it accelerated aging markers in humans. This is the study Johnson cited as a factor in his decision. Most earlier assessments used one or two clocks, so the breadth of this analysis is what made it striking. It remains a preprint, not peer-reviewed, but it flipped the burden of proof.
2. The PEARL trial (published April 2025). AgelessRx ran the largest human trial of rapamycin to date: 114 adults, 48 weeks, double-blind and placebo-controlled, with intermittent low-dose rapamycin. It found the drug was safe and well-tolerated, but the benefits were modest: women on 10 mg weekly saw increased lean muscle mass and less self-reported pain; people on 5 mg weekly reported better emotional well-being and general health. No dramatic anti-aging signal.
3. The side-effect profile is now documented, not anecdotal. Chronic rapamycin use in humans is associated with impaired lipid profiles, insulin resistance, glucose intolerance, increased infection risk from immunosuppression, and increased resting heart rate. Johnson experienced several of these directly. Rapamycin is not FDA approved for anti-aging or preventive use, and anyone considering it needs routine lab monitoring under medical supervision.
If you want the broader longevity-drug context, read the metformin longevity debate and the NMN and NAD+ evidence review. If the epigenetic-clocks angle caught your attention, biological age tests are worth understanding before you trust any single number.
The rapamycin reality check
Johnson did not take rapamycin casually. He had a medical team, constant lab work, and five years of dose titration, and he still got burned. Run through this checklist before you even think about it.
The Rapamycin Reality Check
Check every box you can honestly claim. Then hit the button.
For information only, not medical advice. Talk to your doctor before changing anything.
Frequently asked questions
Is rapamycin FDA approved for anti-aging?
No. Rapamycin (sirolimus) is FDA approved as an immunosuppressant for organ transplant patients and for certain cancers and lung conditions. It is not approved for anti-aging or preventive longevity use. Off-label use requires medical supervision and routine lab monitoring.
How much did Bryan Johnson spend on his anti-aging experiment?
Johnson has said his Project Blueprint program cost up to $2 million per year at its peak, covering a medical team, diagnostics, pharmaceuticals, peptides, and strict lifestyle interventions. The regimen is publicly documented and constantly revised.
How long did Bryan Johnson take rapamycin?
Nearly five years. He began experimenting in 2019 and stopped in September 2024, after trying weekly, biweekly, and alternating dose schedules ranging from 5 to 13 milligrams.
What side effects did Bryan Johnson report?
Intermittent skin and soft-tissue infections, abnormal lipid readings, elevated glucose levels, and an increased resting heart rate. He said dosage adjustments did not resolve them, which is why he discontinued the drug entirely.
What did the 2024 preprint on rapamycin and aging clocks find?
The preprint assessed rapamycin across 16 epigenetic aging clocks and found it accelerated aging markers in humans, contrary to expectations from the mouse data. It is a preprint and not yet peer-reviewed, but Johnson cited it as a factor in his decision to stop.
Is Bryan Johnson still doing his longevity protocol?
Yes. He discontinued rapamycin but continues his broader Blueprint protocol, which he still documents publicly and revises as new data arrives. The rapamycin chapter was one failed experiment inside a much larger program.
Related Articles:
- Unleashing Human Potential: Biohackers World Conference & Expo 2025
- Biohacking Your Way to Optimal Health: Harnessing the Power of Science for Enhanced Well-Being
- Best Biohacking Podcasts You Should Listen to Today!